| Browse All

Immatics N.V. (IMTX)

Healthcare | Biotechnology | Tübingen, Germany | NasdaqCM
11.25 USD +11.25 (0.000%) ⇧ (April 20, 2026, 4 p.m. EDT)

Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 18, 2026, 10:41 p.m. EDT

The 'Strong Buy' analyst consensus is generating a dangerous rating inflation on IMTX; the market is rightly warning against value traps in a biosimilar company with -65% revenue growth and negative gross margins. Despite the shares being up significantly, the waterfall of Open Interest in OTM puts signals institutional capitulation or active de-spiking before a potential bankruptcy restructuring rather than a sustainable recover.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.029765
AutoETS0.029777
AutoARIMA0.029777
MSTL0.030896

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 71%
H-stat 0.87
Ljung-Box p 0.039
Jarque-Bera p 0.000
Excess Kurtosis 2.43
Attribute Value
Sector Healthcare
Debt to Equity Ratio 3.23
Revenue per Share 0.394
Market Cap 1,508,586,496
Forward P/E -6.34
Beta 1.34
Website https://www.immatics.com

As of April 18, 2026, 10:41 p.m. EDT: Speculators are positioning defensively. Despite a 29.0% rise in the underlying price to $11.17, the Open Interest (OI) profile heavily favors downside protection. For the 2026-04-17 expiration, 100% of expiring volume in $9 and $10 strikes is concentrated in Puts, while $11.00 is the ATM anchor for Calls but gains little OI. Long-term puts ($7-$8 strikes) show high IV (5.0) relative to calls, indicating a heavy skew towards hedging rather than directional bullish speculation.


Info Dump

Attribute Value
52 Week Change 1.6041667
Address1 Paul-Ehrlich-Strasse 15-19
All Time High 18.42
All Time Low 0.005
Ask 11.27
Ask Size 1
Average Analyst Rating 1.0 - Strong Buy
Average Daily Volume10 Day 295,090
Average Daily Volume3 Month 447,263
Average Volume 447,263
Average Volume10Days 295,090
Beta 1.337
Bid 11.21
Bid Size 1
Book Value 4.260294
City Tübingen
Compensation As Of Epoch Date 1,767,139,200
Country Germany
Crypto Tradeable 0
Currency USD
Current Price 11.25
Current Ratio 11.718
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 11.29
Day Low 10.8
Debt To Equity 3.23
Display Name Immatics
Earnings Timestamp 1,772,717,400
Earnings Timestamp End 1,778,070,600
Earnings Timestamp Start 1,778,070,600
Ebitda -172,875,008
Ebitda Margins 0.0
Enterprise To Ebitda -6.102
Enterprise To Revenue 21.856
Enterprise Value 1,054,884,480
Eps Current Year -1.75
Eps Forward -1.77311
Eps Trailing Twelve Months -1.9
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 49 7071 5397 900
Fifty Day Average 10.0804
Fifty Day Average Change 1.1695995
Fifty Day Average Change Percent 0.11602709
Fifty Two Week Change Percent 160.41667
Fifty Two Week High 12.41
Fifty Two Week High Change -1.1599998
Fifty Two Week High Change Percent -0.093472995
Fifty Two Week Low 3.94
Fifty Two Week Low Change 7.31
Fifty Two Week Low Change Percent 1.8553299
Fifty Two Week Range 3.94 - 12.41
Financial Currency EUR
First Trade Date Milliseconds 1,544,625,000,000
Float Shares 69,330,612
Forward Eps -1.77311
Forward P E -6.344784
Free Cashflow -128,190,248
Full Exchange Name NasdaqCM
Full Time Employees 589
Gmt Off Set Milliseconds -14,400,000
Gross Margins -2.80873
Gross Profits -135,566,000
Has Pre Post Market Data 1
Held Percent Insiders 0.17918
Held Percent Institutions 0.76458
Implied Shares Outstanding 134,096,576
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Long Name Immatics N.V.
Market us_market
Market Cap 1,508,586,496
Market State PRE
Max Age 86,400
Message Board Id finmb_8986547
Most Recent Quarter 1,767,139,200
Net Income To Common -196,447,008
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 1,507,245,514
Number Of Analyst Opinions 8
Open 11.09
Operating Cashflow -176,626,000
Operating Margins -1.9675599
Payout Ratio 0.0
Phone 49 7071 5397 0
Pre Market Change 0.23999977
Pre Market Change Percent 2.1333313
Pre Market Price 11.49
Pre Market Time 1,776,759,087
Previous Close 0.0
Price Eps Current Year -6.428571
Price Hint 2
Price To Book 2.640663
Price To Sales Trailing12 Months 31.255676
Profit Margins 0.0
Quick Ratio 11.072
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.0
Region US
Regular Market Change 11.25
Regular Market Change Percent 0.0
Regular Market Day High 11.29
Regular Market Day Low 10.8
Regular Market Day Range 10.8 - 11.29
Regular Market Open 11.09
Regular Market Previous Close 0.0
Regular Market Price 11.25
Regular Market Time 1,776,715,201
Regular Market Volume 260,141
Return On Assets -0.18079
Return On Equity -0.37103
Revenue Growth -0.649
Revenue Per Share 0.394
Sand P52 Week Change 0.34445214
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 134,096,576
Shares Percent Shares Out 0.0385
Shares Short 5,165,069
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 5,160,792
Short Name Immatics N.V.
Short Percent Of Float 0.0563
Short Ratio 8.54
Source Interval 15
Symbol IMTX
Target High Price 25.0
Target Low Price 11.0
Target Mean Price 18.75
Target Median Price 18.0
Total Cash 469,336,992
Total Cash Per Share 3.5
Total Debt 15,635,000
Total Revenue 48,266,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield NaN
Trailing Eps -1.9
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 8.826075
Two Hundred Day Average Change 2.4239254
Two Hundred Day Average Change Percent 0.27463233
Type Disp Equity
Volume 260,141
Website https://www.immatics.com
Zip 72,076